AMRI has been awarded a seven-year contract for an active ingredient under clinical evaluation.
AMRI reported that its subsidiary, Albany Molecular Research, located in Holywell, Wales, United Kingdom, has been awarded a seven-year contract for the development and manufacture of an active ingredient under clinical evaluation by the Defense Science and Technology Laboratory, acting on behalf of the United Kingdom’s Secretary of State for Defense, the Department of National Defense of Canada, and Minister of Defense of the Kingdom of the Netherlands.
AMRI will initially work on the development and scale-up of the investigational drug, and the manufacture and supply for use during Phase I clinical trials. If the trials are successful, AMRI could become the commercial manufacturer of the product for distribution to the government partners of this contract, including the UK, the Netherlands, and Canada.
